Welcome to Ziarco
Ziarco is a private, clinical stage biotechnology company developing products to treat chronic inflammatory diseases with a focus on inflammatory skin disorders, in particular atopic dermatitis and psoriasis. These diseases impact the well-being of millions of children and adults globally by severely reducing quality of life.
The Company is progressing its lead programmes through clinical proof-of-concept studies in atopic dermatitis and psoriasis.
Inflammatory Skin Disorders
Chronic inflammatory skin disorders such as atopic dermatitis (eczema) and psoriasis are very common conditions, yet many patients are poorly treated with existing therapies.
A once-daily oral antagonist of the histamine H4 receptor being developed for the treatment of atopic dermatitis and psoriasis.
A potent, long-acting, inhibitor of cPLA2 being developed for the topical treatment of atopic dermatitis.
News and Events
Ziarco will be presenting results of the Phase 2a clinical study of ZPL-389 in atopic dermatitis at EAACI.